Irbesartan ? bohater badań PRIME, czyli o sukcesie ?nieskonsumowanym? :

Krzysztof J.  Filipiak

PDF (Język Polski)

Published: Sep 30, 2011

Krzysztof J. Filipiak

I Katedra i Klinika Kardiologii Warszawskiego Uniwersytetu Medycznego

Abstract

None

How to Cite

Filipiak , K. J. (2011). _the hero of PRIME trial ? the story of ?not consumed? success. Medycyna Faktow (J EBM), 4(3(12), 19-21. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2514

Issue

Vol 4 No 3(12) (2011)

Section

Articles

References

1. Haller H., Ito S., Izzo J.L. et al.: Olmesartan for the delay or prevention of microalbuminuria in diabetestype 2. NEJM 2011; 364: 907-917.

Most read articles by the same author(s)

Krzysztof J. Filipiak , Czy antagoniści receptorów angiotensynowych AT1 (sartany) mogą zwiększać ryzyko wystąpienia choroby nowotworowej? Komentarz kardiologa i hipertensjologa , OncoReview: Vol 2 No 1(5) (2012)
Krzysztof J. Filipiak , Every clinician dilemma: ramipril, telmisartan, valsartan ? what, when and whom to prescribe? , Medycyna Faktow (J EBM): Vol 5 No 4(17) (2012)
Krzysztof J. Filipiak , Filip M. Szymański , Andrzej Steciwko , Grzegorz Opolski , The effectiveness of lipid-lowering therapy in Poland - results of the OSLO-Pol study , Medycyna Faktow (J EBM): Vol 4 No 3(12) (2011)
Krzysztof J. Filipiak , ASTEROID Trial. Why important? Why to come back to it after 5 years? , Medycyna Faktow (J EBM): Vol 3 No 4(9) (2010)
Krzysztof J. Filipiak , JUPITER trial ? should we decrease the LDL-cholesterol concentrations below 60 mg/dl in patients with ?normal? lipid level? , Medycyna Faktow (J EBM): Vol 2 No 1(2) (2009)

Article Sidebar

Main Article Content

Abstract

Article Details

References

Most read articles by the same author(s)